The use of drug delivery systems to offer increased safety and utility of ocular therapeutics is a rapidly evolving and evergrowing
field. Controlled release systems have been employed to both reformulate existing drugs and design new drugs
to meet the high potential for commercial interest and patient benefit. The Ocular Drug Delivery Focus Group will support
the mission of CRS by engaging researchers, industry representatives, and regulatory experts in the advancement of
technologies designed to protect or restore vision. The members of the Focus Group are expected to be paid members
of the Controlled Release Society, independent of their membership category. We will also reach out to former or inactive
members of CRS and other non-members in the vision research community whose work may benefit from the Focus
Group to encourage their participation. This may include notable professional societies in ophthalmology like the
Association for Research in Vision and Ophthalmology (ARVO) and the International Society for Eye Research (ISER).
The members of the Focus Group are expected
to be paid members of the Controlled Release Society, independently of their membership category.